With 2020 underway, HDA’s John M. Gray provided perspective on the vital role of pharmaceutical distributors and the Alliance’s policy priorities as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.
“A new decade presents an opportunity for reflection,” said Gray. “For HDA and our pharmaceutical distributor members, [the new year] finds us reexamining the value our industry provides to the larger healthcare ecosystem while reassessing our priorities and anticipating what is around the corner.
In his column, Gray highlighted HDA’s 2019 study, The Role of Distributors in the U.S. Health Care Industry, to reiterate how distributors serve as the backbone of the U.S. healthcare system through the core and value-added services they offer to trading partners. He also forecasted four potential scenarios that might affect distributors and the pharmaceutical supply chain in the near future.
In the piece, Gray further detailed several legislative and regulatory priorities that will shape HDA’s activities in the year ahead, including:
- Addressing drug pricing and importation priorities;
- Mitigating the opioid crisis, including continuing collaborative efforts to the educate the public on the safe use and disposal of pain medications through Allied Against Opioid Abuse; and,
- Sustaining efforts to implement Drug Supply Chain Security Act-related requirements, given the dispenser requirements that will go into effect this November.
ABOUT THE HEALTHCARE DISTRIBUTION ALLIANCE
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s nonprofit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.